Development
NP Life Sciences Health Industry Group Inc.
NPLS
$0.0539
-$0.0962-64.09%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 120.44% | 348.20% | 277.14% | 191.43% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 120.44% | 348.20% | 277.14% | 191.43% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 120.44% | 348.20% | 277.14% | 191.43% | -- |
| SG&A Expenses | 58.24% | 104.82% | 10.44% | 20.32% | -21.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.24% | 104.82% | 10.44% | 20.32% | -21.19% |
| Operating Income | 1,770.97% | 552.97% | 118.67% | 71.25% | 97.40% |
| Income Before Tax | 1,754.84% | 551.89% | 118.67% | 71.25% | 97.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1,754.84% | 551.89% | 118.67% | 71.25% | 97.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,754.84% | 551.89% | 118.67% | 71.25% | 97.40% |
| EBIT | 1,770.97% | 552.97% | 118.67% | 71.25% | 97.40% |
| EBITDA | -- | -- | -- | -- | 127.81% |
| EPS Basic | -- | 600.00% | 118.75% | 73.33% | 100.00% |
| Normalized Basic EPS | 800.00% | 466.67% | 109.09% | 60.00% | 94.44% |
| EPS Diluted | -- | 600.00% | 118.75% | 73.33% | 100.00% |
| Normalized Diluted EPS | 800.00% | 466.67% | 109.09% | 60.00% | 94.44% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |